Octreotide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Octreotide: From Acromegaly to Vulvar Inverted Follicular Keratosis
One-Sentence Summary
Octreotide is a somatostatin analogue originally used for acromegaly, hyperpituitarism and carcinoid syndrome. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis, but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acromegaly, hyperpituitarism, carcinoid syndrome (the Singapore licence records contain no indication text) |
| Predicted New Indication | Vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Octreotide is a somatostatin analogue, and its efficacy in acromegaly and carcinoid syndrome is established. Its known effects are mediated through somatostatin receptors, mainly in pituitary and neuroendocrine tissue.
The data compiled for this report show no plausible link between somatostatin-receptor activity and vulvar inverted follicular keratosis. The very high TxGNN score (0.996) is not backed by any trial or publication. The adjacent prediction, seborrheic keratosis (score 0.995), is similarly unsupported, which suggests the score may reflect a knowledge-graph neighbourhood effect rather than true biological evidence.
Other top predictions also lack support. Addison disease (rank 4) and adrenocortical insufficiency (rank 8) have only indirect, low-tier literature (a case report, a small negative physiological study, and a pituitary case series). These do not show that octreotide treats adrenal insufficiency.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the leading prediction, vulvar inverted follicular keratosis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11638P | SANDOSTATIN LAR FOR INJECTION 30 mg | Injection | Not stated in the registration record |
| SIN03808P | SANDOSTATIN INJECTION 0.1 mg/ml | Injection | Not stated in the registration record |
| SIN11637P | SANDOSTATIN LAR FOR INJECTION 20 mg | Injection | Not stated in the registration record |
Safety Considerations
Contraindications / cautions suggested by the knowledge graph (not label text): hyperglycaemia, diabetes mellitus, diabetic ketoacidosis, hypoglycaemia, hypothyroidism (including myxedema and congenital hypothyroidism), liver disease and cirrhosis, gallbladder disease and gallstones (cholelithiasis, cholecystolithiasis, choledocholithiasis), ileus and intestinal obstruction, sudden cardiac arrest, heart conduction disease, kidney failure, uremia, and vitamin B12 deficiency. These are model-derived associations and must be verified against the package insert.
Drug Interactions: 100 interactions were found, all of Moderate level among those listed. The main ones involve glucose-lowering drugs, so blood glucose should be monitored when combined with them:
- Insulins (aspart, degludec, detemir, glargine, glulisine, human regular/isophane/inhaled)
- Metformin, acarbose, chlorpropamide, glimepiride
- GLP-1 agonists (albiglutide, dulaglutide, semaglutide)
- DPP-4 inhibitors (alogliptin, linagliptin)
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin)
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score, with no trials, no literature, and no identifiable mechanistic link. Octreotide has a notable safety profile in glucose, gallbladder, thyroid and cardiac conduction disorders, so no action is justified without further evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (currently a blocking gap for safety screening)
- Mechanism of action data (e.g. from DrugBank) to assess any somatostatin-receptor link to the predicted condition
- Any preclinical or clinical evidence on somatostatin-receptor expression or octreotide activity in the predicted skin condition
- Review of the other top-ranked predictions for better-supported candidates, since none currently has trial support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.